Single-arm trial reports orelabrutinib response in high-risk lymphoma
In a prospective, multicenter, single-arm phase II trial conducted at four centers in China, orelabrutinib plus R-CDOP was associated with ...
In a prospective, multicenter, single-arm phase II trial conducted at four centers in China, orelabrutinib plus R-CDOP was associated with ...
© 2025 Scienmag - Science Magazine
© 2025 Scienmag - Science Magazine